Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia (Q28285577)

cannabis and schizophrenia

Europe PubMed Central

title

Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia (English)

0 references

main subject

schizophrenia

0 references

cannabinoids

0 references

1 reference

based on heuristic

inferred from title

author name string

Kirsten R Müller-Vahl

series ordinal

1

0 references

Hinderk M Emrich

series ordinal

2

0 references

language of work or name

English

0 references

publication date

July 2008

0 references

published in

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

0 references

volume

8

0 references

issue

7

0 references

page(s)

1037-48

0 references

cites work

Schizophrenia, “Just the Facts”: What we know in 2008

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Examining an affect regulation model of substance abuse in schizophrenia. The role of traits and coping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use and psychosis: a longitudinal population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use and age at onset of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Tests of causal linkages between cannabis use and psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Clinical characteristics of adolescents later hospitalized for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use and the risk of later schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis induced dopamine release: an in-vivo SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Elevated plasma dopamine metabolites in cannabis psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

The acute effects of cannabinoids on memory in humans: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Reduced binocular depth inversion in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Reduced binocular depth inversion in regular cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Endocannabinoid signalling in the blood of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Brain volume changes in the first year of illness and 5-year outcome of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Altered brain tissue composition in heavy marijuana users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Effects of frequent marijuana use on brain tissue volume and composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis and brain morphology in recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

What causes the onset of psychosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1037